Interview
CEO Mike Kujak Interviewed by Medtech Insight
August 6, 2024
In a recent exclusive interview with Citeline Commercial’s Medtech Insight, Mike Kujak, CEO of Francis Medical, revealed the latest developments regarding Vanquish—our revolutionary advancement for treating prostate cancer with water vapor therapy. Kujak’s insights offer a glimpse into how this innovative device is set to redefine standards in prostate cancer treatment.
Medtech Insight Article: Vanquishing Prostate Cancer Without Debilitating Side Effects – Francis Medical CEO On Water Vapor Ablation
More on Mike on our Leadership Page
Recent Posts
Francis Medical Announces Strategic Financing to Accelerate Commercial Expansion and Complete Prostate Cancer Management Indication PMA Program
MAPLE GROVE, Minn., November 10, 2026 – Francis Medical, Inc., a medical device company dedicated to advancing minimally invasive therapies for urological cancers, today announced that it has entered into an agreement for financing led by Johnson & Johnson through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc (JJDC).
Francis Medical Announces Northwell Urology Group Performs First Commercial Vanquish® Water Vapor Ablation Procedure in New York
LAKE SUCCESS, NY, August 5, 2026, - Samir S. Taneja, MD, a urologic oncologist, chairman of the Department of Urology at Northwell Health and professor of urology at the Donald and Barbara Zucker School of Medicine, has performed the first commercial Vanquish® Water Vapor Ablation (Vanquish System) procedure in New York state, marking a significant milestone for patients in the region seeking a minimally invasive prostate care option.
Francis Medical Announces Orange County Urology Associates Becomes First in California to Integrate Vanquish® Water Vapor Ablation into Routine Prostate Care
Maple Grove, Minn., July 7th, 2026 – Daniel Su, MD, a urologist at Orange County Urology Associates (OCUA), has performed the first commercial Vanquish® Water Vapor Ablation procedures in the state of California, offering patients a new minimally invasive Focal Therapy option as part of the group’s prostate care service. The procedure was completed within a single outpatient visit and did not require a hospital stay. Beyond the clinical milestone, Dr. Su’s experience highlights something equally important: how this technology can be adopted into an existing urology practice.
Federal law (USA) restricts this device to sale by or on the order of a physician.
Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.